Treatment of brain cancer
Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.
1. A method of treating brain metastases in a patient suffering from ErbB2 positive breast cancer with brain metastases, comprising administering to the patient a therapeutically effective amount of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, in combination with trastuzumab and capecitabine.
2. The method of claim 1 , wherein the patient has been previously treated for breast cancer.
3. The method of claim 2 , wherein the patient has been previously treated with trastuzumab for breast cancer.
4. The method of claim 1 , wherein N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is administered to the patient in an oral dosage form.
5. The method of claim 4 , wherein the oral dosage form is administered from about 100 m to about 1600 m per day.
6. The method of claim 2 , wherein N4-(4-((1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethy1-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is administered to the patient in an oral dosage form.
7. The method of claim 6 , wherein the oral dosage form is administered to the patient from about 100 mg to about 1600 mg per day.
8. A method of treating a patient suffering from breast cancer with brain metastases, comprising administering to the patient a therapeutically effective amount of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, in combination with trastuzumab and capecitabine.
9. The method of claim 8 , wherein the breast cancer is ErbB2 positive.
10. The method of claim 8 , wherein the patient has been previously treated for breast cancer.
11. The method of claim 10 , wherein the patient has been previously treated with trastuzumab for breast cancer.
12. The method of claim 8 , wherein N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is administered to the patient in an oral dosage form.
13. The method of claim 12 , wherein the oral dosage form is administered from about 100 mg to about 1600 mg per day.
14. The method of claim 9 , wherein N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is administered to the patient in an oral dosage form.
15. The method of claim 14 , wherein the oral dosage form is a solid dispersion oral dosage form.
16. The method of claim 15 , wherein the tablet is administered to the patient from about 100 mg to about 1600 mg per day.